Osteoporos
Senast uppdaterad: Senast reviderad:
Sakkunnig:Hans Lundin
Definition:
En systemisk skelettsjukdom med minskad benmassa och förändringar i benvävnadens mikroarkitektur som medför skört skelett och ökad risk för frakturer.
Förekomst:
Förekomsten av osteoporos är mycket högre hos kvinnor än hos män och ökar kraftigt med åldern. I Sverige inträffar varje år cirka 60 000 lågenergifrakturer, varav 18 000 är höftfrakturer.
Symtom:
Osteoporos ger sällan några symtom innan en fraktur inträffar och den låga bentätheten är viktig att identifiera på grund av att den är en riskfaktor för kommande frakturer.
Kliniska fynd:
En fraktur efter litet våld är det viktigaste tecknet på osteoporos men kliniska fynd kan också vara lågt BMI, längdminskning >3 cm jämfört med maxlängd som ung eller uttalad thorakal kyfos som tecken på tidigare kotfrakturer.
Diagnostik:
Beslut om benspecifik läkemedelsbehandling grundas på en samlad klinisk bedömning. Särskilt stark behandlingsindikation föreligger vid fraktur i kota eller höft.
Behandling:
Benspecifika läkemedel, men också livsstilsförändringar såsom ökad fysisk aktivitet, träning av styrka och balans samt rökstopp.
- Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646–50. PMID: 8506892. PubMed
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129. PMID: 7941614. PubMed
- Warriner AH, Patkar NM, Curtis JR et al. Which fractures are most attributable to osteoporosis? J Clin Epidemiol. 2011 Jan;64(1):46-53. PMID: 21130353 PubMed
- Ström O, Borgström F, Åkesson K, Ljunggren Ö, Salomonsson S. Svensk Osteoporosvård - utmaningar och förändringsarbete. Quantify Research AB; 2014. www.svos.se
- Svedbom A, Hernlund E, Ivergård M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. rch Osteoporos. 2013; 8(1-2): 137. doi: 10.1007/s11657-013-0137-0. DOI
- Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgström F, Kanis JA; SCOPE review panel of the IOF. Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos. 2022 Jan 26;17(1):23. doi: 10.1007/s11657-021-00969-8. PMID: 35079919 PubMed
- Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669-74. PMID: 11095169. PubMed
- Starup-Linde J, Rosendahl SB, Storgaard M, Langdahl B. Management of osteoporosis in patients living with HIV - a systematic review and meta-analysis. J Acquir. Immune Defic Syndr 2020; 83: 1-8. pmid:31809356 PubMed
- Crndall CJ, Larson JCLaCroix AZ, et al. Risk of Subsequent Fractures in Postmenopausal Women After Nontraumatic vs Traumatic Fractures. JAMA Intern Med 2021. pmid:34096979 PubMed
- Nationella riktlinjer för rörelseorganens sjukdomar (hämtad 2021-10-06) www.socialstyrelsen.se
- Ny rekommendation för läkemedelsbehandling vid osteoporos för att förhindra benskörhetsfrakturer. Nyheter Läkemedelsverket. Hämtad 2020-05-15 www.lakemedelsverket.se
- Almén A , Leitz w, Nyman U. Stråldoser och riskuppskattning vid radiologisk diagnostik. Appendix III, S 544. SBU-rapport (2002): Blodpropp - förebyggande, diagnostik och behandling av venös tromboembolism. www.sbu.se
- Shevroja E, Lamy O, Kohlmeier L, Koromani F, Rivadeneira F, Hans D. Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice. J Clin Densitom 2017;20:334–45. PMID: 28734710 PubMed
- Läkemedel vid osteoporos för att förhindra benskörhetsfrakturer - behandlingsrekommendation. Läkemedelsverket, 2020 www.lakemedelsverket.se
- Liu M, Guo L, Pei Y, Li N et al. Efficacy of zoledronic acid in treatment of osteoporosis in men and women-a meta-analysis. Int J Clin Exp Med 2015;8:3855–61. PMID: 26064284 PubMed
- Bone HG, Wagman RB, Brandi ML et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513–23. PMID: 28546097 PubMed
- Avenell A, Mak JC, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014 Apr 14;2014(4):CD000227. doi: 10.1002/14651858.CD000227.pub4. PMID: 24729336 PubMed
- Weaver CM, Alexander DD, Boushey CJ et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 2016;27:367–76. PMID: 26510847 PubMed
- Chapuy MC, Arlot ME, Duboeuf F, Brun J et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637–42. PMID: 1331788. PubMed
- De Kam D, Smulders E, Weerdesteyn V, Smits-Engelsman BC. Exercise interventions to reduce fall-related fractures and their risk factors in individuals with low bone density: a systematic review of randomized controlled trials. Osteoporos Int. 2009 Dec;20(12):2111-25. PMID: 19421702.
- Gillespie LD, Robertson MC, Gillespie W et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD007146. doi: 10.1002/14651858.CD007146.pub3. The Cochrane Library
- Sherrington C, Whitney JC, Lord SR, et al. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008 Dec;56(12):2234-43. PMID: 19093923. PubMed
- Pirruccio K, Yoon YM, Ahn J et al. Fractures in Elderly Americans Associated With Walking Leashed Dogs. JAMA Surg. 2019 Mar 6. PMID: 30840050 PubMed
- Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 2014; 3: CD001255. doi:10.1002/14651858.CD001255.pub5 DOI
- Koike T, Orito Y, Toyoda H, et al. External hip protectors are effective for the elderly with higher-than-average risk factors for hip fractures. Osteoporosis Int 2009; 20: 1613.20. PMID:19137351. PubMed
- Thorin MH, Wihlborg A, Åkesson K, Gerdhem P. Smoking, smoking cessation, and fracture risk in elderly women followed for 10 years. Osteoporos Int 2016;27:249–55. PMID: 26302684 PubMed
- Zhang X, Yu Z, Yu M, Qu X. Alcohol consumption and hip fracture risk. Osteoporos Int 2015;26:531–42. PMID: 25266483 PubMed
- Nordiska Näringsrekommendationer 2012. Livsmedelsverket. www.livsmedelsverket.se
- Eriksen EF. Treatment of osteopenia. Rev Endocr Metab Disord 2012;13:209–23. PMID: 21710179 PubMed
- Quandt SA, Thompson DE, Schneider DL et al, Fracture Intervention Trial Research Group. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005;80:343–9. PMID: 15757015 PubMed
- Grey A, Bolland M, Mihov B et al. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial. J Bone Miner Res Off J Am Soc Bone Miner Res 2014;29:166–72. PMID: 23761303 PubMed
- Grey A, Bolland MJ, Horne A et al. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. CMAJ Can Med Assoc J 2017;189:E1130–6. PMID: 28893875 PubMed
- Reid IR, Horne AM, Mihov B et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. PMID: 30575489 PubMed
- Deardorff WJ, Cenzer I, Nguyen B, Lee SJ. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2021 Nov 22:e216745. doi: 10.1001/jamainternmed.2021.6745. Epub ahead of print. PMID: 34807231 PubMed
- Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155. doi: 10.1002/14651858.CD001155.pub2. The Cochrane Library
- Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22. PMID: 17476007 PubMed
- Freemantle N, Cooper C, Diez-Perez A et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 2013;24:209–17. PMID: 22832638 PubMed
- Popp AW, Senn R, Curkovic et al. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 2017;28:1995–2002. PMID: 28299378 PubMed
- Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, et al. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res 2018;33:190–8. PMID: 29105841 PubMed
- Romosozumab (Evenity™) nytt osteoporosläkemedel för kvinnor med mycket hög frakturrisk. Hämtad 2021-01-26 vardgivare.skane.se
- Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017 Oct 12;377(15):1417-1427. PMID: 28892457. PubMed
- Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3183-3193.PMID: 29931216.
- Lv F, Cai X, Yang W, Gao L, Chen L, Wu J, Ji L. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 2020 Jan;130:115121. PMID: 31678488. PubMed
- Kharazmi M, Schilcher J, Hallberg P, Michaëlsson K. Atypisk femurfraktur en allvarlig komplikation till bisfosfonater. Lakartidningen.se 2019-09-16. www.lakartidningen.se
- Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ 2016;353:i3365. PMID: 27353596 PubMed
- Schilcher J, Koeppen V, Aspenberg P, Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014;371:974–6. PMID: 25184886 PubMed
- Khan M, Cheung AM, Khan AA. Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinol Metab Clin North Am 2017;46:181–92. PMID: 28131131 PubMed
- Rikshöft. Rikshöft årsrapport 2016. 2017 rikshoft.se
- Hayashida S, Soutome S, Yanamoto S et al. Evaluation of the Treatment Strategies for Medication-Related Osteonecrosis of the Jaws (MRONJ) and the Factors Affecting Treatment Outcome: A Multicenter Retrospective Study with Propensity Score Matching Analysis. J Bone Miner Res 2017;32:2022–9. PMID: 28585700 PubMed
- Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet 2013. doi:doi:10.1016/S0140-6736(13)60856-9 DOI
- Landfeldt E, Ström O, Robbins S, Borgström F. Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA 2012;23:433–43. PMID: 21286686 PubMed
- Bell KJ, Hayen A, Glasziou P et al. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. J Bone Miner Res Off J Am Soc Bone Miner Res 2016;31:1767–73. PMID: 27027655 PubMed
- Austin M, Yang YC, Vittinghoff E, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012 Mar;27(3):687-93. PMID: 22095631. PubMed
- Black DM, Abrahamsen B, Bouxsein ML et al. Atypical Femur Fractures – Review of epidemiology, relationship to bisphosphonates, prevention and clinical management. Endocr Rev. 2018 Aug 29. PMID: 30169557 PubMed
- Jung SY, Suh HS, Park JW, Kwon JW. Drug Holiday Patterns and Bisphosphonate-Related Osteonecrosis of the Jaw. Oral Dis. Oral Dis. 2018 Aug 28. PMID: 30153366 PubMed
- Black DM, Schwartz AV, Ensrud KE et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38. PMID: 17190893 PubMed
- Maraka S, Kennel KA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ 2015;351:h3783. PMID: 26333528 PubMed
- Adler RA, El-Hajj Fuleihan G et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res Off J Am Soc Bone Miner Res 2016;31:16–35. PMID: 26350171 PubMed
- Schwartz AV, Bauer DC, Cummings SR et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res Off J Am Soc Bone Miner Res 2010;25:976–82. PMID: 20200926 PubMed
- Anagnostis P, Paschou SA, Mintziori G al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 2017;101:23–30. PMID: 28539165 PubMed
- Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med 2012; 366: 225-33. New England Journal of Medicine
- Cummings SR, Lui L-Y, Eastell R, Allen IE. Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis. JAMA Intern Med 2019. pmid:31424486 PubMed
- Experten svarar: Bentäthetsmätningar. Tidningen Evidens. Janusinfo. Region Stockholm. Hämtad 2020-12-16 janusinfo.se
- Hans Lundin, med dr, specialist i allmänmedicin vid sektionen för Allmänmedicin, Karolinska institutet